P500: Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.ECCO’23 CopenhagenYear: 2023
Authors: Iborra Colomino, M.I.(1)*;Ferreiro-Iglesias, R.(2);Martín-Arranz, M.D.(3);Mesonero-Gismero, F.(4);Mínguez, A.(1);Porto Silva, S.(2);García-Ramírez, L.(5);García de la Filia, I.(4);Bastida, G.(1);Nieto García, L.(2);Suárez Ferrer, C.(3);Aguas, M.(1);Barreiro de Acosta, M.(2);Nos, P.(1);
(1)La Fe University and Polytechnic Hospital, Department of Gastroenterology, Valencia, Spain;(2)University Hospital of Santiago De Compostela, Department of Gastroenterology and Hepatology, Santiago de Compostela, Spain;(3)University Hospital La Paz, Gastroenterology Department, Madrid, Spain;(4)University Hospital Ramón y Cajal, Department of Gastroenterology, Madrid, Spain;(5)University Hospital La Paz, Foundation for Biomedical Research, Madrid, Spain;
P501: Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohortECCO’23 CopenhagenYear: 2023
Authors: Ochsenkuehn, T.(1)*;Tillack-Schreiber, C.(2);Bader, F.(3);Maximilian, S.(3);Szokodi, D.(4);Tomelden, J.(5);Waggershauser, C.(6);Braun, I.(4);Schnitzler, F.(7);
(1)Isarklinikum, Department of Gastroenterology- Hospital IBD center Munich, Munich, Germany;(2)VIVAQ-MVZ, IBD-center Munich, Munich, Germany;(3)Isarklinikum, Surgery, Munich, Germany;(4)VIVAQ-MVZ, IBD center, Munich, Germany;(5)Isarklinikum, IBD center, Munich, Germany;(6)University of Munich, IBD center, Munich, Germany;(7)University of Munich, IBD center Munich, Munich, Germany;
P502: Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and costECCO’23 CopenhagenYear: 2023
Authors: Nguyen, A.(1,2,3)*;Gibson, P.(1,2);Upton , R.(4,5);Mould, D.(4);Sparrow, M.P.(1,2);
(1)Monash University, Central Clinical School, Melbourne, Australia;(2)Alfred Health, Department of Gastroenterology, Melbourne, Australia;(3)Charité – Universitätsmedizin Berlin, Medical Department of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(4)Projections Research Inc., Projections Research Inc., Phoenixville, United States;(5)University of South Australia, Clinical and Health Sciences, Adelaide, Australia;
P503: The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQECCO’23 CopenhagenYear: 2023
Authors: Rezazadeh Ardabili, A.(1,2)*;van Esser, D.(1);Wintjens, D.(1);Cilissen, M.(1);Deben, D.(3);Mujagic, Z.(1,2);Russ, F.(4);Stassen, L.(2,5);van Bodegraven, A.(4);Wong, D.(3);Winkens, B.(6);Jonkers, D.(1,2);Romberg-Camps, M.(4);Pierik, M.(1,2);
(1)Maastricht University Medical Center+, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Maastricht, The Netherlands;(2)Maastricht University Medical Center+, School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht, The Netherlands;(3)Zuyderland Medical Centre, Department of Clinical Pharmacy- Clinical pharmacology and Toxicology, Sittard-Geleen, The Netherlands;(4)Zuyderland Medical Centre, Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen, The Netherlands;(5)Maastricht University Medical Center+, Department of Surgery, Maastricht, The Netherlands;(6)Maastricht University, Department of Methodology and Statistics- Care and Public Health Research Institute CAPHRI, Maastricht, The Netherlands;
P504: Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cellsECCO’23 CopenhagenYear: 2023
Authors: Atreya, R.(1)*;Abreu, M.T.(2);Krueger, J.G.(3);Eyerich, K.(4,5);Sachen, K.(6);Greving, C.(6);Hammaker, D.(6);Bao, P.(6);Lacy, E.(7);Sarabia, I.(6);Deming, J.(6);Elloso, M.M.(8);Ritchlin, C.(9);McInnes, I.B.(10);Allez, M.(11);Fourie, A.(6);
(1)Erlangen University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;(2)University of Miami, Leonard Miller School of Medicine, Miami- FL, United States;(3)The Rockefeller University, Laboratory for Investigative Dermatology, New York- NY, United States;(4)University of Freiburg, Medical Center, Freiburg, Germany;(5)Karolinska Institute, Department of Medicine - Division of Dermatology and Venereology, Stockholm, Sweden;(6)Janssen Research and Development- LLC, Immunology, San Diego- CA, United States;(7)Janssen Research and Development- LLC, Immunology, Spring House- PA, United States;(8)Janssen Scientific Affairs- LLC, Immunology, Horsham- PA, United States;(9)University of Rochester, Department of Medicine - Allergy/Immunology and Rheumatology, Rochester, United States;(10)University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom;(11)Hôpital Saint-Louis, Université Paris Cité, Paris, France;
P505: Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn's disease: results from “long vedo” italian multicenter studyECCO’23 CopenhagenYear: 2023
Authors: MocciMD FRCP, G.(1)*;Maconi , G.(2);Onidi, F.M.(1);Cataletti, G.(2);Elisei , W.(3);Scaldaferri, F.(4);Lorenzetti , R.(5);Pagnini, C.(6);Scarcelli, A.(7);Graziani , M.G.(6);Di Paolo , M.C.(8);Pranzo, G.(9);Luppino, I.(9);Monterubbianesi, R.(10);Faggiani, R.(3);Ferronato, A.(11);Savarino, E.(12);Pica, R.(13);Cocco, A.(13);Rodino, S.(14); Sebkova, L.(15);Zampaletta, C.(16);Gaiani, F.(17);Fanigliulo, L.(18);Allegretta , L.(19);Cuomo, A.(20);Donnarumma, L.(21);Della Valle , N.(22);Forti, G.(23);Antonelli, E.(24);Bassotti , G.(24);Iannelli, C.(25);Aragona, G.(26);Lauria, A.(27);Piergallini, S.(28);Colucci, R.(29);Binaghi, L.(1);Meucci, C.(30);Papa, A.(4);Tursi, A.(31);
(1)Arnas- Brotzu Hospital- Gastroenterology Unit, Department of Internal Medicine, Cagliari, Italy;(2)Division of Gastroenterology- “L. Sacco” University Hospital, Division of Gastroenterology- “L. Sacco” University Hospital, Milan, Italy;(3)A.O. “S. Camillo-Folanini”, Division of Gastroenterology- A.O. “S. Camillo-Forlanini”, Rome, Italy;(4)Division of Internal Medicine and Gastroenterology- Policlinico Universitario “A. Gemelli” IRCCS Foundation, Department of Medical and Surgical Sciences, Rome, Italy;(5)“Nuovo Regina Margherita” Territorial Hospital, 17 Division of Gastroenterology-, Rome, Italy;(6)Division of Gastroenterology- “S. Giovanni - Addolorata” Hospital, Division of Gastroenterology- “S. Giovanni - Addolorata” Hospital, Rome, Italy;(7)3 Division of Gastroenterology- “San Salvatore” Hospital-, 3 Division of Gastroenterology- “San Salvatore” Hospital-, Pesaro, Italy;(8)Division of Gastroenterology- “S. Giovanni - Addolorata” Hospital-, Division of Gastroenterology- “S. Giovanni - Addolorata” Hospital-, Rome, Italy;(9)Division of Gastroenterology- “Annunziata” Hospital-, Division of Gastroenterology- “Annunziata” Hospital-, Cosenza, Italy;(10)A.O. “S. Camillo-Forlanini”, Division of Gastroenterology- A.O. “S. Camillo-Forlanini”, Rome, Italy;(11)Digestive Endoscopy Unit- ULSS7 Pedemontana-, Digestive Endoscopy Unit- ULSS7 Pedemontana-, Santorso, Italy;(12)Gastroenterology Unit- Azienda Ospedale-Università di Padova AOUP-, Gastroenterology Unit- Azienda Ospedale-Università di Padova AOUP-, Padua, Italy;(13)Division of Gastroenterology- IBD Unit- “S. Pertini” Hospital, Division of Gastroenterology- IBD Unit- “S. Pertini” Hospital, Rome, Italy;(14)Division of Gastroenterology- “Ciaccio-Pugliese” Hospital- Catanzaro- Italy, Division of Gastroenterology- “Ciaccio-Pugliese” Hospital- Catanzaro- Italy, Catanzaro, Italy;(15)Division of Gastroenterology- “Belcolle” Hospital-, Division of Gastroenterology- “Belcolle” Hospital-, Viterbo, Italy;(16)Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery- University of Parma-, Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery- University of Parma, Parma, Italy;(17)Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery- University of Parma-, Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery- University of Parma-, Parma, Italy;(18)Division of Gastroenterology- “S.S. Annunziata” Hospital-, Division of Gastroenterology- “S.S. Annunziata” Hospital-, Taranto, Italy;(19)Division of Gastroenterology- “Santa Caterina Novella” Hospital-, Division of Gastroenterology- “Santa Caterina Novella” Hospital-, Galatina, Italy;(20)Division of Gastroenterology- “Umberto I” Hospital- Nocera Inferiore, Division of Gastroenterology- “Umberto I” Hospital- Nocera Inferiore, Nocera Inferiore SA, Italy;(21)Division of Gastroenterology- “Umberto I” Hospital-, Division of Gastroenterology- “Umberto I” Hospital-, Nocera Inferiore SA, Italy;(22)Division of Gastroenterology- A.O. “Ospedali Riuniti”-, Division of Gastroenterology- A.O. “Ospedali Riuniti”-, Foggia, Italy;(23)Division of Digestive Endoscopy- “S. Maria Goretti” Hospital-, Division of Digestive Endoscopy- “S. Maria Goretti” Hospital-, Latina, Italy;(24)Gastroenterology & Hepatology Section- Department of Medicine & Surgery- University of Perugia-, Gastroenterology & Hepatology Section- Department of Medicine & Surgery- University of Perugia-, Perugia, Italy;(25)Department of Health Science- University of Catanzaro-, Department of Health Science- University of Catanzaro-, Catanzaro, Italy;(26)Division of Gastroenterology- “Guglielmo da Saliceto" Hospital-, Division of Gastroenterology- “Guglielmo da Saliceto" Hospital-, Piacenza, Italy;(27)Division of Gastroenterology- A.O. “Bianchi-Melacrino-Morelli”-, Division of Gastroenterology- A.O. “Bianchi-Melacrino-Morelli”-, Reggio Calabria, Italy;(28)Division of Gastroenterology- IBD Unit- “A. Murri” Hospital-, Division of Gastroenterology- IBD Unit- “A. Murri” Hospital-, Fermo, Italy;(29)Digestive Endoscopy Unit- “San Matteo degli Infermi” Hospital- Spoleto PG- Italy, Digestive Endoscopy Unit- “San Matteo degli Infermi” Hospital- Spoleto PG- Italy, Spoleto, Italy;(30)Division of Gastroenterology- “T. Maresca” Hospital-, Division of Gastroenterology- “T. Maresca” Hospital-, Torre del Greco Na, Italy;(31)Territorial Gastroenterology Service- ASL BAT, Territorial Gastroenterology Service- ASL BAT, Andria, Italy;
P506: Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn's disease by baseline disease severityECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Patel, K.(2);Torres, E.A.(3);Lakatos, P.L.(4,5);Seidelin, J.(6);Fleisher, M.(7);Ford, S.(8);Remple, V.(8);Lacerda, A.P.(8);Anyanwu, S.(8);Garrison, A.(8);Panés, J.(9);
(1)Charité - Universitätsmedizin, Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)St George's NHS Foundation Hospitals, Department of Gastroenterology and Hepatology, London, United Kingdom;(3)University of Puerto Rico Medical Sciences Campus, Department of Medicine- Division of Gastroenterology- School of Medicine, San Juan, Puerto Rico;(4)McGill University, Division of Gastroenterology, Montreal, Canada;(5)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(6)University of Copenhagen, Department of Gastroenterology and Hepatology- Herlev Hospital, Copenhagen, Denmark;(7)Borland-Groover Clinic, Gastroenterology, Jacksonville, United States;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)CIBERehd, Hospital Clínic Barcelona- IDIBAPS, Barcelona, Spain;
P507: United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) surveyECCO’23 CopenhagenYear: 2023
Authors: Travis, S.(1)*;Bleakman, A.(2);Dubinsky, M.(3);Rubin, D.(4);Panaccione, R.(5);Hibi, T.(6);Kayhan, C.(2);Gibble, T.H.(2);Sapin, C.(2);Flynn, E.(2);Atkinson, C.(7);Schreiber, S.(8);
(1)University of Oxford, Translational Gastroenterology Unit- John Radcliffe Hospital, Oxford, United Kingdom;(2)Eli Lilly and Company, Immunology, Indianapolis, United States;(3)Icahn School of Medicine, Pediatric Gastroenterology, New York, United States;(4)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(5)University of Calgary, Inflammatory Bowel Disease Group, Alberta, Canada;(6)Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(7)Adelphi Real World, Research, Cheshire- England, United Kingdom;(8)University Hospital Schleswig-Holstein- Kiel University, Clinic for Internal Medicine 1, Kiel, Germany;
P508: Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Simpson, K.(1)*;Inniss, S.(2);Fragkos, K.C.(1);Wood, C.P.J.(1);Smith, A.(2);Rahman, F.Z.(1);
(1)University College London Hospitals NHS Foundation Trust, Gastrointestinal Services, London, United Kingdom;(2)University College London, Eastman Dental Institute, London, United Kingdom;
P509: Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.ECCO’23 CopenhagenYear: 2023
Authors: Jenkinson, P.(1)*;Plevris, N.(2);Lyons, M.(2);Gros Alcalde, B.(2);Derikx, L.(2);Constantine-Cooke, N.(3);Arnott, I.(2);Jones, G.(4);Lees, C.(2);
(1)NHS Lothian, Colorectal Surgery, Rosewell, United Kingdom;(2)Western General Hospital, GI Department, Edinburgh, United Kingdom;(3)University of Edinburgh, Institute of genetics and cancer., Edinburgh, United Kingdom;(4)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;
P510: Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.ECCO’23 CopenhagenYear: 2023
Authors: Matos Coelho Bernardo, S.(1)*;Fernandes, S.(1);Serrazina, J.(1);Rodrigues, I.(1);Botto, I.(1);Bronze, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Santos, P.M.D.(1);Tato Marinho, R.(1);Correia, L.(1);
(1)Hospital de Santa Maria- CHULN, Department of Gastrenterology and Hepatology, Lisbon, Portugal;
P512: The counts of white blood cells are not predictive for long-term remission under treatment with thiopurines: a three year Japanese multi-center retrospective cohort study.ECCO’23 CopenhagenYear: 2023
Authors: Kiyohara, H.(1,2)*;Yamazaki, H.(3);Moriya, K.(4);Akimoto, N.(5);Kawai, S.(6);Kobayashi, T.(1);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Keio University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(3)Kyoto University- Graduate School of Medicine, Section of Clinical Epidemiology- Department of Community Medicine, Kyoto, Japan;(4)Nara Medical University, Department of Gastroenterology and Hepatology, Nara, Japan;(5)Nippon Medical School- Graduate School of Medicine, Department of Gastroenterology, Tokyo, Japan;(6)Osaka General Medical Center, Department of Gastroenterology and Hepatology, Osaka, Japan;IBD Terakoya Group
P513: Prospective study on patients' satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Navarro Llavat, M.(1)*;García-Bosch, O.(1);Castro-Poceiro, J.(1);Bargalló García, A.(1);Ruiz Arroyo , D.(1);Navas Bravo , Y.(1);Erice Muñoz, E.(1);Barquero Declara, D.(1);Mata Bilbao, A.(1);Martín Llahí , M.(1);Ariza Solé, X.(1);Hernández Ballesteros, C.(1);Juan Juan , A.(1);Bustamante Robles, K.(1);Berbel Comas, C.(1);Blasco Pelicano, A.(1);Albareda Riera, M.(2);Domènech Morral , E.(3);
(1)Hospital Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(2)Hospital Moisès Broggi, Endocrinology and Nutrition, Sant Joan Despí, Spain;(3)Hospital Germans Trias i Pujol and Centro de Investigaciones en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Badalona, Spain;
P514: Serum levels of Klotho in inflammatory bowel disease: an exploratory studyECCO’23 CopenhagenYear: 2023
Authors: Hernandez-Camba, A.(1,2);Rodriguez-Jimenez, J.(1)*;Carrillo Palau, M.(3);Ramos Lopez, L.(3);Perez-Mendez , L.(4,5);Martin-Nuñez , E.(6);Alonso, I.(3);Vela, M.(1);Hernandez Alverez Builla, N.(3);Arranz, L.(1);Hernandez, A.(3);Ferraz Amaro, I.(7);Navarro‐Gonzalez, J.F.(6,8,9);
(1)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(2)Nursing School Nuestra Señora de Candelaria- La Laguna University, Anatomy and Histology, Santa Cruz de Tenerife, Spain;(3)Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain;(4)Hospital Universitario de Nuestra Señora de Candelaria y Gerencia de Atención Primaria, Clinical Epidemiology and Bioestadistics Division- Research Unit, Santa Cruz de Tenerife, Spain;(5)Center for Biomedical Research in Respiratory Diseases Network CIBER, Instituto de Salud Carlos III, Madrid, Spain;(6)Hospital Universitario Nuestra Señora de Candelaria, Research Unit, Santa Cruz de Tenerife, Spain;(7)Hospital Universitario de Canarias, Rheumatology, La Laguna, Spain;(8)La Laguna University, Institute of Biomedical Technologies, La Laguna, Spain;(9)Hospital Universitario Nuestra Señora de Candelaria, Nephrology, Santa Cruz de Tenerife, Spain;
P515: Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternativeECCO’23 CopenhagenYear: 2023
Authors: Hammoudi, N.(1)*;Hassid, D.(1);Bonnet, J.(1);Tran Minh, M.L.(1);Baudry, C.(1);Chedouba, L.(1);Vauthier, A.(1);Gornet, J.M.(1);Allez, M.(1);
(1)APHP Saint Louis, Gastroenterology, Paris, France;
P516: Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Caldera, F.(1)*;Maddux, R.(2);Ungaro, R.(3);Kaur, A.(2);Brown, E.(2);Hu, S.(2);Sheffield, J.K.(2);Silva, D.(2);Harris, S.(2);Cree, B.A.C.(4);
(1)University of Wisconsin School of Medicine and Public Health, Gastroenterology and Hepatology, Madison, United States;(2)Bristol Myers Squibb, Clinical Research, Princeton, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)University of California San Francisco, Weill Institute for Neurosciences- Department of Neurology, San Francisco, United States;
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Ramos Lopez, L.(1);Ramos-Díaz, R.(2);Alonso-Abreu, I.(1);Mourani-Padron, I.(2);Carrillo-Palau, M.(1);Reygosa, M.C.(1)*;Medina-Chico, S.(1);Gutierrez-Nicolas, F.(3);Nazco-Casariego, G.J.(3);Hernandez-Guerra, M.(4);
(1)Hospital Universitario De Canarias, IBD Unit. Gastroenterology Department, La Laguna, Spain;(2)Hospital Universitario de Canarias, Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC, La Laguna, Spain;(3)Hospital Universitario de Canarias, Hospital Pharmacy Department, La Laguna, Spain;(4)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;
P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)ECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Lichtenstein, G.(2);Nakase, H.(3);Armuzzi, A.(4);Kucharzik, T.(5);Levy, G.(6);Palac, H.(6);Kujawski, M.(6);Klaff, J.(6);Cheon, J.H.(7);
(1)University of Calgary Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada;(2)University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, United States;(3)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(4)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(5)Klinikum Lüneburg, Division of Gastroenterology and Hepatology, Lüneburg, Germany;(6)AbbVie Inc, Immunology, North Chicago, United States;(7)Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;
